Company Encyclopedia
View More
name
UNI-BIO GROUP
00690.HK
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, an oral medication for the treatment of diabetes. It also develops prescription drugs, such as UOS003(oral PTH) for the treatment of osteoporosis; Uni-GLP-1, a non-insulin treatment candidate that stimulates the incretin pathway for the treatment of type 2 diabetes and obesity; and pre-clinical stage biopharmaceutical products for wound care and ophthalmology.
1.377 T
00690.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking12/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE26.27%A
    • Profit Margin15.49%A
    • Gross Margin81.90%A
  • Growth ScoreB
    • Revenue YoY15.97%B
    • Net Profit YoY-7.60%C
    • Total Assets YoY14.16%B
    • Net Assets YoY22.45%A
  • Cash ScoreB
    • Cash Flow Margin645.44%C
    • OCF YoY15.97%B
  • Operating ScoreA
    • Turnover1.13A
  • Debt ScoreB
    • Gearing Ratio31.15%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shareholders of UNI-BIO GROUP will deposit stocks into HSBC Hong Kong, with a storage market value of HKD 113 million

    According to the latest information from the Hong Kong Stock Exchange, on September 23, shareholders of UNI-BIO GROUP deposited shares into HSBC Hong Kong, with a warehouse market value of HKD 113 million, accounting for 12.33%. Recently, UNI-BIO GROUP announced that its wholly-owned subsidiary Beijing Bokan Jian Gene Technology Co., Ltd. signed a strategic cooperation agreement with Sinovac Biotech Ltd., granting Sinovac exclusive commercialization rights for the innovative osteoporosis treatment drug Bogu Tai® in six countries (cooperation areas): Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico

    Zhitong·
    HK
    00690
    +0.89%
    Zhitong·
    HK
    00690
    +0.89%

    UNI-BIO GROUP: Signed a strategic cooperation agreement with SDKX to expand the global market for BoguTai®

    UNI-BIO GROUP has signed a strategic cooperation agreement with SDKX, authorizing SDKX to exclusively commercialize Bogu Tai® in six countries: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. Since its launch in March 2024, the drug has performed exceptionally well, with expected revenue growth of 248.9% year-on-year in the first half of 2025. This cooperation provides a significant opportunity for Bogu Tai® to enter the market, with anticipated revenue by the end of 2026, supporting the group's globalization expansion strategy

    Zhitong·
    HK
    00690
    +0.89%
    SH
    688136
    +0.21%
    Zhitong·
    HK
    00690
    +0.89%
    SH
    688136
    +0.21%

    "Performance" UNI-BIO GROUP's interim net profit of HKD 75.96 million increased by 12.7%, no dividend declared

    UNI-BIO GROUP announced its interim results for the six months ended June, with revenue of HKD 310 million, an increase of 13.4% year-on-year. It recorded a net profit of HKD 75.96 million, a growth of 12.7%, with earnings per share of HKD 1.27. No dividend was declared

    AASTOCKS·
    HK
    00690
    +0.89%
    AASTOCKS·
    HK
    00690
    +0.89%

    UNI-BIO GROUP released its interim results, with a net profit of HKD 75.955 million, a year-on-year increase of 12.7%

    UNI-BIO GROUP released its mid-term results for 2025, with revenue of HKD 310 million, a year-on-year increase of 13.4%; net profit of HKD 75.955 million, a year-on-year increase of 12.7%; and basic earnings per share of HKD 1.27. The growth in performance is attributed to the expansion of sales channels, increased demand for BoguTai®, and market attention to already listed drugs, reflecting the group's strategic effectiveness in operational efficiency, cost control, and commercial execution

    Zhitong·
    HK
    00690
    +0.89%
    Zhitong·
    HK
    00690
    +0.89%

    UNI-BIO GROUP: The listing application for Isavuconazole capsules has been officially accepted by the National Medical Products Administration of China

    UNI-BIO GROUP announced that its application for the listing of isavuconazole sulfate capsules has been accepted by the National Medical Products Administration of China, with approval expected in the second half of 2026. This novel antifungal drug will provide safer treatment options for patients with invasive fungal infections. The group also plans to ensure high-quality production and market penetration by expanding its sales network and upgrading its production lines. The global antifungal drug market is expected to grow significantly, with the Chinese market projected to reach approximately 30 billion yuan by 2030

    Zhitong·
    HK
    00690
    +0.89%
    Zhitong·
    HK
    00690
    +0.89%
    © 2025 Longbridge｜Disclaimer